Assessment of Multivalent Vaccine Strategies for Combatting Shigella and Salmonella Infections in Preclinical Studies - Summary - MDSpire

Assessment of Multivalent Vaccine Strategies for Combatting Shigella and Salmonella Infections in Preclinical Studies

  • By

  • Roberta Di Benedetto

  • Rebecca Nappini

  • Salvatore Gemmellaro

  • Federica Boretto

  • Valentina Caradonna

  • Martina Carducci

  • Paola Cescutti

  • Omar Rossi

  • Francesca Mancini

  • Francesco Berlanda Scorza

  • Simona Rondini

  • Carlo Giannelli

  • Renzo Alfini

  • Francesca Micoli

  • April 22, 2026

  • 0 min

Share

Objective:

To evaluate the feasibility and immunogenicity of a novel hexavalent vaccine combining Shigella and Salmonella antigens, addressing the urgent need due to rising antimicrobial resistance.

Key Findings:
  • The hexavalent vaccine formulation did not significantly impact the humoral immune response to any of the components, with p-values indicating statistical significance.
  • Shigella GMMA effectively served as a carrier for the S. Paratyphi A O-antigen, enhancing the formulation's efficiency.
  • The combined vaccine strategy has the potential to enhance vaccine acceptance and reduce delivery costs, potentially increasing immunization rates.
Interpretation:

A multivalent vaccine targeting both Shigella and Salmonella could address significant public health needs, particularly in regions where these pathogens co-circulate, potentially reducing disease burden and improving health outcomes.

Limitations:
  • The study is based on preclinical animal models; human clinical trials are necessary to confirm findings and assess safety.
  • Potential regulatory challenges and market acceptance in LMICs remain to be addressed, including cost-effectiveness and integration into existing immunization programs.
Conclusion:

The development of a hexavalent vaccine combining Shigella and Salmonella antigens shows promise for improving immunization strategies and addressing antimicrobial resistance, with significant implications for public health.

Original Source(s)

Assessment of Multivalent Vaccine Strategies for Combatting Shigella and Salmonella Infections in Preclinical Studies

  • by Roberta Di Benedetto, Rebecca Nappini, Salvatore Gemmellaro, Federica Boretto, Valentina Caradonna, Martina Carducci, Paola Cescutti, Omar Rossi, Francesca Mancini, Francesco Berlanda Scorza, Simona Rondini, Carlo Giannelli, Renzo Alfini, Francesca Micoli

  • April 22, 2026

Related Content

31 Live Births Reported Following Uterus Transplant

Single-center series details maternal, obstetric, and neonatal outcomes among recipients with uterine-factor infertility

‘Patient autonomy’ has nothing to do with childhood vaccine policies

Senate Report Details Early Myocarditis Signals After COVID-19 Vaccination

Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.